- Complicated Urinary Tract Infection (draft issued February 23, 2012); ²
 - Uncomplicated Gonorrhea;
- Complicated Intra-Abdominal Infection (draft issued September 28, 2012);
 - · Diabetic Foot Infection; and
- Hospital-Acquired and Ventilator-Associated Bacterial Pneumonia (draft issued November 26, 2010).⁴

IV. Emerging Resistance to Antibacterial Drugs

In addition to facilitating antibacterial drug development, the task force recognizes the need to address the issue of emerging drug resistance. The public health need caused by the lack of a robust pipeline is further compounded by the diminishing effectiveness of currently available antibacterial drugs due to emerging drug resistance. Therefore, we are seeking comment on strategies to preserve the utility of antibacterial drugs.

V. Categories for Public Comment

We request the following information from the public:

- Novel study designs to expedite the development of new antibacterial drugs;
- Comments on our prioritized list of proposed draft or final guidance development; and
- Potential strategies intended to slow the rate of emerging drug resistance.

When responding to this notice, please include the category or categories that your response addresses.

VI. Comments

Interested persons may submit either electronic comments to http://www.regulations.gov or written comments regarding this document to the Division of Dockets Management (see ADDRESSES). It is only necessary to send one set of comments. Identify comments with the docket number found in brackets in the heading of this document. When responding, include the category or categories that your response addresses as listed in section V of this document. Received comments may be seen in the Division of Dockets

Management between 9 a.m. and 4 p.m., Monday through Friday, and will be posted to the docket at http:// www.regulations.gov.

Dated: May 24, 2013.

Leslie Kux.

Assistant Commissioner for Policy.

[FR Doc. 2013-12925 Filed 5-30-13; 8:45 am]

BILLING CODE 4160-01-P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

National Institute of Diabetes and Digestive and Kidney Diseases; Cancellation of Meeting

Notice is hereby given of the cancellation of the National Institute of Diabetes and Digestive and Kidney Diseases Special Emphasis Panel, June 13, 2013, 8:00 a.m. to June 13, 2013, 4:00 p.m., St. Gregory Hotel, 2033 M Street NW., Washington, DC, 20036 which was published in the **Federal Register** on April 10, 2013, 78 FR 21381.

This meeting is being cancelled due to a scheduling conflict.

Dated: May 24, 2013.

David Clary,

Program Analyst, Office of Federal Advisory Committee Policy.

[FR Doc. 2013–12883 Filed 5–30–13; 8:45 am]

BILLING CODE 4140-01-P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

Center for Scientific Review; Notice of Closed Meetings

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. App.), notice is hereby given of the following meetings.

The meetings will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

Name of Committee: Center for Scientific Review Special Emphasis Panel; Member Conflict: Cognition and Perception.

Date: June 19, 2013.

Time: 2:00 p.m. to 3:30 p.m.

Agenda: To review and evaluate grant applications.

Place: National Institutes of Health, 6701 Rockledge Drive, Bethesda, MD 20892, (Telephone Conference Call).

Contact Person: Jane A Doussard-Roosevelt, Ph.D., Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 3184, MSC 7848, Bethesda, MD 20892, (301) 435–4445, doussarj@csr.nih.gov.

Name of Committee: Center for Scientific Review Special Emphasis Panel; Member Conflict: Societal and Ethical Issues in Research.

Date: June 20, 2013.

Time: 4:00 p.m. to 5:00 p.m.

Agenda: To review and evaluate grant applications.

Agenda: National Institutes of Health, 6701 Rockledge Drive, Bethesda, MD 20892.

Contact Person: Lisa Steele, Ph.D., Scientific Review Officer, PSE IRG, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 3139, MSC 7770, Bethesda, MD 20892, 301–594– 6594, steeleln@csr.nih.gov.

Name of Committee: Center for Scientific Review Special Emphasis Panel; PAR 12– 251: Review of B/START Applications.

Date: June 21, 2013.

Time: 11:00 a.m. to 5:00 p.m.

Agenda: To review and evaluate grant applications.

Place: National Institutes of Health, 6701 Rockledge Drive, Bethesda, MD 20892, (Telephone Conference Call).

Contact Person: Jose H Guerrier, Ph.D., Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 5218, MSC 7852, Bethesda, MD 20892, 301–435– 1137, guerriej@csr.nih.gov.

Name of Committee: Center for Scientific Review Special Emphasis Panel; RFA–RM– 12–018: NIH Director's Early Independence Awards Review.

Date: June 24-25, 2013.

Time: 8:00 a.m. to 6:00 p.m.

Agenda: To review and evaluate grant applications.

Place: Ritz Carlton Hotel, 1150 22nd Street, NW., Washington, DC 20037.

Contact Person: Weijia Ni, Ph.D., Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 3184, MSC 7848, Bethesda, MD 20892, (301) 237–9918, niw@csr.nih.gov.

Name of Committee: Genes, Genomes, and Genetics Integrated Review Group; Therapeutic Approaches to Genetic Diseases Study Section.

Date: June 26, 2013.

Time: 8:30 a.m. to 1:30 p.m.

Agenda: To review and evaluate grant applications.

Place: National Institutes of Health, 6701 Rockledge Drive, Bethesda, MD 20892, (Virtual Meeting).

Contact Person: Elaine Sierra-Rivera, Ph.D., Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 6184, MSC 7804, Bethesda, MD 20892, 301–435– 1779, riverase@csr.nih.gov.

² Complicated Urinary Tract Infection Draft Guidance available at http://www.fda.gov/ downloads/Drugs/ GuidanceComplianceRegulatoryInformation/

Guidances/UCM070981.pdf.

3 Complicated Intra-Abdominal Infection Draft Guidance available at http://www.fda.gov/downloads/Drugs/

GuidanceComplianceRegulatoryInformation/ Guidances/UCM321390.pdf.

⁴Hospital Acquired and Ventilator Associated Pneumonia Draft Guidance available at http:// www.fda.gov/downloads/Drugs/ GuidanceComplianceRegulatoryInformation/ Guidances/UCM234907.pdf.